Engineering synthetically modified insulin for glucose-responsive diabetes therapy

Engineering synthetically modified insulin for glucose-responsive diabetes therapy

Though a suite of different insulin variants have been used clinically to provide greater control over pharmacokinetics, no clinically used insulin can tune its potency and/or bioavailability in a glucose-dependent manner. In order to improve therapy for diabetic patients, a vision has been the deve...

Full description

Bibliographic Details
Main Authors: Webber, Matthew (Author), Anderson, Daniel Griffith (Author), Langer, Robert S (Author)
Other Authors: Massachusetts Institute of Technology. Department of Chemical Engineering (Contributor), Massachusetts Institute of Technology. Institute for Medical Engineering & Science (Contributor), Harvard University- (Contributor), Massachusetts Institute of Technology. Department of Biological Engineering (Contributor), Koch Institute for Integrative Cancer Research at MIT (Contributor)
Format: Article
Language:English
Published: Informa UK Limited, 2019-08-23T14:26:54Z.
Subjects:
Article
Online Access:Get fulltext

Internet

Get fulltext

Similar Items